Genedrive's Saudi Arabian distribution partner inks MoU with Ministry of Health.

Pharmacogenetic testing business Genedrive said on Tuesday that its exclusive distribution partner in the Kingdom of Saudi Arabia, iDeal iDea for Medical Equipment Technology, has signed a memorandum of understanding with the Saudi Arabian Ministry of Health.

Genedrive
28 October 2025 08:26:08

Source: Sharecast

Genedrive said the scope of the MoU was to pilot its MT-RNR1 ID Kit for potential national implementation under a national initiative called, "Generations Hear".

The MOU was signed by Hatim Najjar, founder and chief executive of iDeal iDea, Dr Abdullah Al-Sohimi, General Director of Specialized Centers at Ministry of Health, and Dr Salem Baharoon, Deputy Minister for Therapeutic Services, Ministry of Health.

Dr Gino Miele, CEO of genedrive plc, said: "We are delighted with the signing of this MOU, which builds further on our commercial traction in Saudi Arabia and aligns perfectly to the long-term Saudi health goals. We are grateful to our valued partners at iDeal iDea for their support and look forward to progressing through pilot phase with the goal of implementation at national level."

As of 0825 GMT, Genedrive shares were up 15.17% at 0.51p.

Reporting by Iain Gilbert at Sharecast.com

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.